Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2014 2
2016 2
2017 2
2019 2
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Effects of metabolic cancer therapy on tumor microenvironment.
Hyroššová P, Milošević M, Škoda J, Vachtenheim J Jr, Rohlena J, Rohlenová K. Hyroššová P, et al. Front Oncol. 2022 Dec 13;12:1046630. doi: 10.3389/fonc.2022.1046630. eCollection 2022. Front Oncol. 2022. PMID: 36582801 Free PMC article. Review.
PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner.
Hyroššová P, Aragó M, Moreno-Felici J, Fu X, Mendez-Lucas A, García-Rovés PM, Burgess S, Figueras A, Viñals F, Perales JC. Hyroššová P, et al. Cancer Metab. 2021 Jan 7;9(1):1. doi: 10.1186/s40170-020-00236-3. Cancer Metab. 2021. PMID: 33413684 Free PMC article.
Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M.
Aragó M, Moreno-Felici J, Abás S, Rodríguez-Arévalo S, Hyroššová P, Figueras A, Viñals F, Pérez B, Loza MI, Brea J, Latorre P, Carrodeguas JA, García-Rovés PM, Galdeano C, Ginex T, Luque FJ, Escolano C, Perales JC. Aragó M, et al. Among authors: hyrossova p. Biomed Pharmacother. 2020 Jan;121:109601. doi: 10.1016/j.biopha.2019.109601. Epub 2019 Nov 15. Biomed Pharmacother. 2020. PMID: 31739159 Free article.
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F. Lahiguera Á, et al. Among authors: hyrossova p. EMBO Mol Med. 2020 Jun 8;12(6):e11217. doi: 10.15252/emmm.201911217. Epub 2020 May 13. EMBO Mol Med. 2020. PMID: 32400970 Free PMC article.
13 results